标题
BCMA-targeted immunotherapy for multiple myeloma
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-09-18
DOI
10.1186/s13045-020-00962-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
- (2020) Deepu Madduri et al. BLOOD
- Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2020) Bai-Yan Wang et al. BLOOD
- A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial
- (2020) Chenggong Li et al. BLOOD
- Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset
- (2020) Enrique Zudaire et al. BLOOD
- Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
- (2020) Chunrui Li et al. BLOOD
- First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
- (2020) Luciano J. Costa et al. BLOOD
- AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo
- (2020) Shih-Feng Cho et al. BLOOD
- Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
- (2020) Jesus G. Berdeja et al. BLOOD
- Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
- (2020) Nikhil C. Munshi et al. JOURNAL OF CLINICAL ONCOLOGY
- Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
- (2020) Jesus G. Berdeja et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
- (2020) Yuru Nie et al. Biomarker Research
- Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
- (2019) Suzanne Trudel et al. Blood Cancer Journal
- Mortality of lymphoma and myeloma in China, 2004–2017: an observational study
- (2019) Weiping Liu et al. Journal of Hematology & Oncology
- Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
- (2019) Juanjuan Zhao et al. Journal of Hematology & Oncology
- Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
- (2019) Delong Liu et al. Journal of Hematology & Oncology
- Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
- (2019) Tiantian Ma et al. ANNALS OF HEMATOLOGY
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Soluble Markers of Antibody Secreting Cell Function as Predictors of Infection Risk in Rheumatoid Arthritis
- (2019) Maria J. Gutierrez et al. Journal of Immunology Research
- B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma
- (2019) Yu-Tzu Tai et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma
- (2019) Erik Eckhert et al. Immunotherapy
- Engineering switchable and programmable universal CARs for CAR T therapy
- (2019) Delong Liu et al. Journal of Hematology & Oncology
- Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
- (2019) Hejin Jia et al. Journal of Hematology & Oncology
- Targeting mTOR for cancer therapy
- (2019) Hui Hua et al. Journal of Hematology & Oncology
- Target selection for CAR-T therapy
- (2019) Jianshu Wei et al. Journal of Hematology & Oncology
- Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells
- (2019) Haiming Chen et al. LEUKEMIA RESEARCH
- Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
- (2019) Marijke Timmers et al. Frontiers in Immunology
- γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
- (2019) Margot J. Pont et al. BLOOD
- Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
- (2019) Bo Yu et al. Journal of Hematology & Oncology
- Relapsed refractory multiple myeloma: a comprehensive overview
- (2019) Abdul Hamid Bazarbachi et al. LEUKEMIA
- Efficacy and Safety of CAR-T Therapy with Safety Switch Targeting Bcma for Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Clinical Study
- (2019) Weijun Fu et al. BLOOD
- Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
- (2019) Dennis Cooper et al. BLOOD
- Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)
- (2019) Caitlin L. Costello et al. BLOOD
- Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma
- (2019) Ethan G. Thompson et al. BLOOD
- Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells
- (2019) Liang Lin et al. BLOOD
- B Cell Maturation Antigen-Specific CAR T Cells for Relapsed or Refractory Multiple Myeloma: A Meta-Analysis
- (2019) Nico Gagelmann et al. BLOOD
- Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma
- (2019) Lijie Xing et al. BLOOD
- Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma
- (2019) Jin Jie et al. BLOOD
- Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2019) Noopur S. Raje et al. BLOOD
- Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
- (2019) Alfred L. Garfall et al. BLOOD
- Updated Phase 1 Results of a First-in-Human Open-Label Study of Lcar-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (Bcma)
- (2019) Lijuan Chen et al. BLOOD
- Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)
- (2019) Paul G. Richardson et al. BLOOD
- MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells
- (2019) Lijie Xing et al. BLOOD
- Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2019) Katja Weisel et al. BLOOD
- A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
- (2019) Hua Zhang et al. BLOOD
- Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models
- (2019) Patrick R. Hagner et al. BLOOD
- HDP-101, a Novel BCMA-targeted Antibody Conjugated to α-Amanitin, is Active against Myeloma with Preferential Efficacy against Pre-clinical Models of Deletion 17p
- (2019) Ram Kumar Singh et al. Clinical Lymphoma Myeloma & Leukemia
- APRIL and BAFF: novel biomarkers for central nervous system lymphoma
- (2019) Matthias Mulazzani et al. Journal of Hematology & Oncology
- Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
- (2019) Xiao Han et al. Journal of Hematology & Oncology
- CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
- (2019) Delong Liu Journal of Hematology & Oncology
- Chimeric antigen receptor T cell therapies for multiple myeloma
- (2019) Chao Wu et al. Journal of Hematology & Oncology
- Recent updates on CAR T clinical trials for multiple myeloma
- (2019) Quande Lin et al. Molecular Cancer
- A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
- (2019) Zhiling Yan et al. Lancet Haematology
- Incidence and mortality of multiple myeloma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016
- (2019) Jiangmei Liu et al. Journal of Hematology & Oncology
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Investigational Antibody–Drug Conjugates for Treatment of B-lineage Malignancies
- (2018) Alex F. Herrera et al. Clinical Lymphoma Myeloma & Leukemia
- Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
- (2018) Kevin M. Friedman et al. HUMAN GENE THERAPY
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
- (2018) David Porter et al. Journal of Hematology & Oncology
- Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
- (2018) Eric L. Smith et al. MOLECULAR THERAPY
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
- (2018) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
- (2018) De-Xiu Bu et al. Oncotarget
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy
- (2018) Elizabeth L. Siegler et al. Cell Stem Cell
- Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma
- (2018) Sarah Chehab et al. Future Oncology
- HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma.
- (2018) Andreas Pahl et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
- (2018) Robert F. Cornell et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytokine release syndrome: grading, modeling, and new therapy
- (2018) Delong Liu et al. Journal of Hematology & Oncology
- Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
- (2018) Shih-Feng Cho et al. Frontiers in Immunology
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
- (2018) Jinhuan Xu et al. Journal of Hematology & Oncology
- Universal CARs, universal T cells, and universal CAR T cells
- (2018) Juanjuan Zhao et al. Journal of Hematology & Oncology
- Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
- (2018) Suzanne Trudel et al. LANCET ONCOLOGY
- CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
- (2018) Fabio Morandi et al. Frontiers in Immunology
- Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
- (2017) Frank (Xiaohu) Fan et al. JOURNAL OF CLINICAL ONCOLOGY
- Engineering Natural Killer Cells for Cancer Immunotherapy
- (2017) Katayoun Rezvani et al. MOLECULAR THERAPY
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characteristics of BAFF and APRIL factor expression in multiple myeloma and clinical significance
- (2017) Jing Pan et al. Oncology Letters
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
- (2016) Y.-T. Tai et al. BLOOD
- Antibody-drug conjugates—an emerging class of cancer treatment
- (2016) Nikolaos Diamantis et al. BRITISH JOURNAL OF CANCER
- Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
- (2016) Lydia Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma
- (2016) E. Sanchez et al. CLINICAL CANCER RESEARCH
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- (2016) Michael Ghermezi et al. HAEMATOLOGICA
- Linkers Having a Crucial Role in Antibody–Drug Conjugates
- (2016) Jun Lu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo
- (2016) S Hipp et al. LEUKEMIA
- Dependent Coverage under the ACA and Medicaid Coverage for Childbirth
- (2016) Yaa Akosa Antwi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD
- (2016) Saad Usmani et al. ONCOLOGIST
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- (2016) Michael Ghermezi et al. HAEMATOLOGICA
- Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow
- (2015) T Matthes et al. LEUKEMIA
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
- (2015) C.-Y. Wu et al. SCIENCE
- Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma
- (2015) Emmanuelle Le Ray et al. Expert Review of Hematology
- γ-secretase directly sheds the survival receptor BCMA from plasma cells
- (2015) Sarah A. Laurent et al. Nature Communications
- A review of blinatumomab, a novel immunotherapy
- (2015) Matthew J Newman et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Current Treatment for Multiple Myeloma
- (2014) David Avigan et al. NEW ENGLAND JOURNAL OF MEDICINE
- BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma
- (2013) L. Bolkun et al. ANNALS OF HEMATOLOGY
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Regulatory Roles of the Tumor Necrosis Factor Receptor BCMA
- (2013) Christine M. Coquery et al. CRITICAL REVIEWS IN IMMUNOLOGY
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
- (2013) Hua Jiang et al. Molecular Oncology
- PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
- (2013) V. D. Fedorov et al. Science Translational Medicine
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
- (2012) M. Klinger et al. BLOOD
- Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
- (2012) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
- (2012) Hagop Kantarjian et al. LANCET ONCOLOGY
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Classical and/or alternative NF- B pathway activation in multiple myeloma
- (2010) Y. N. Demchenko et al. BLOOD
- B-lymphocyte-induced maturation protein1 up-regulates the expression of B-cell maturation antigen in mouse plasma cells
- (2010) Shaoli Deng et al. MOLECULAR BIOLOGY REPORTS
- Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting
- (2009) Giuliana Cassinelli et al. BIOCHEMICAL PHARMACOLOGY
- APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop
- (2009) Jérôme Moreaux et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
- Identification of new splice variants of the genes BAFF and BCMA
- (2007) Anna S. Smirnova et al. MOLECULAR IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now